Health
Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations – GlobeNewswire
– Second Product Candidate Expected to Enter Clinic in First Half of 2021 – Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal…
Second Product Candidate Expected to Enter Clinic in First Half of 2021
Preclinical Data Underscore Treatment Potential for PBFT02 in Frontotemporal Dementia with Granulin (GRN) Mutations, a Devastating, Progressive Disorder Impacting Adults with No Approved Disease-Modifying Therapy Options
PHILADELPHIA, Jan. 28, 2021 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS)…
-
Noosa News23 hours agoMeasles alert issued across popular south-east attractions
-
General23 hours agoSector warns Coalition’s plan to limit overseas students ‘straight out of Trump’s playbook’
-
General20 hours agoChinese spies, ports and Donald | Scam of the Week
-
Noosa News10 hours agoShow your Anzac Spirit on the ‘Troop Train’